Sriram Venkataraman Net Worth

The estimated Net Worth of Sriram Venkataraman is at least $171 Million dollars as of 13 January 2020. Mr. Venkataraman owns over 1,250,000 units of Osmotica Pharmaceuticals Plc stock worth over $17,461,259 and over the last 8 years he sold OSMT stock worth over $153,207,500. In addition, he makes $57,500 as Director at Osmotica Pharmaceuticals Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Venkataraman OSMT stock SEC Form 4 insiders trading

Sriram has made over 6 trades of the Osmotica Pharmaceuticals Plc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,250,000 units of OSMT stock worth $6,250,000 on 13 January 2020.

The largest trade he's ever made was selling 3,000,000 units of Osmotica Pharmaceuticals Plc stock on 17 March 2017 worth over $36,600,000. On average, Sriram trades about 1,114,583 units every 96 days since 2016. As of 13 January 2020 he still owns at least 15,730,864 units of Osmotica Pharmaceuticals Plc stock.

You can see the complete history of Mr. Venkataraman stock trades at the bottom of the page.

Sriram Venkataraman biography

Sriram Venkataraman serves as Director of the Company. He is also a Partner of Avista Capital Partners, having joined in 2007. Prior to joining Avista Capital Partners, Mr. Venkataraman was a Vice President in the Healthcare Investment Banking group at Credit Suisse Group AG, where he worked from 2001 to 2007. Previously, he worked at GE Healthcare (formerly known as GE Medical Systems) from 1996 to 1999. He currently serves as a director of Inform Diagnostics, Inc., National Spine & Pain Centers Holdings, LLC, OptiNose, Inc., XIFIN, Inc. and Cosette Pharmaceuticals, Inc. and previously served as a director of AngioDynamics, Inc., Lantheus Holdings, Inc. and Zest Anchors, Inc. Mr. Venkataraman holds an M.S. in Electrical Engineering from the University of Illinois, Urbana-Champaign and an M.B.A. from The Wharton School at the University of Pennsylvania. Mr. Venkataraman is being nominated to serve on our board of directors because of his experience in the healthcare industry, his strong finance and management background, and his experience serving as a director of private and public companies.

What is the salary of Sriram Venkataraman?

As the Director of Osmotica Pharmaceuticals Plc, the total compensation of Sriram Venkataraman at Osmotica Pharmaceuticals Plc is $57,500. There are 12 executives at Osmotica Pharmaceuticals Plc getting paid more, with Brian Markison having the highest compensation of $4,338,620.

How old is Sriram Venkataraman?

Sriram Venkataraman is 47, he's been the Director of Osmotica Pharmaceuticals Plc since 2016. There are 12 older and 4 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.

What's Sriram Venkataraman's mailing address?

Sriram's mailing address filed with the SEC is 65 E 55th St #18, New York, NY 10022, USA.

Insiders trading at Osmotica Pharmaceuticals Plc

Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, and Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.

What does Osmotica Pharmaceuticals Plc do?

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.

Complete history of Mr. Venkataraman stock trades at Angiodynamic Inc, Lantheus Inc, OptiNose Inc, and Osmotica Pharmaceuticals Plc

Osmotica Pharmaceuticals Plc executives and stock owners

Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:

• Brian Markison,
  Chairman of the Board, Chief Executive Officer
• Christopher Klein,
  General Counsel, Secretary
• Tina deVries,
  Executive Vice President - Research & Development
• James Schaub,
  Chief Operating Officer, Executive Vice President
• Brian A. Markison,
  Chairman, Pres & CEO
• Christopher A. Klein,
  Gen. Counsel & Sec.
• James D. Schaub,
  Exec. VP & COO
• Dr. Tina Marie deVries,
  Exec. VP of R&D
• Andrew Einhorn,
  Chief Financial Officer
• Fred Weiss,
  Independent Director
• Gregory Cowan,
  Independent Director
• David Burgstahler,
  Director
• Sriram Venkataraman,
  Director
• Juan Vergez,
  Director
• Michael DeBiasi,
  Independent Director
• Lisa Wilson,
  IR Contact Officer
• Joachim Benes,
  Director
• Andrew J. Einhorn CPA,
  Chief Financial Officer
• Jarret Miller,
  Exec. VP of HR
• Sergio Alegre,
  VP of Global Compliance
• Capital Partners Iii Gp, L....,
  
• Ltd Orbit Co Invest A 1 Llc...,
  
• Foundation Harsaul,
  10% owner
• Capital Partners Iii Gp, L....,